A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US Adults.
Christina A RostadRobert L AtmarEmmanuel B WalterSharon FreyJeffery L MeierAmy C ShermanLilin LaiRachel TsongCarol M KaoVanessa RaabeHana M El SahlyWendy A KeitelJennifer A WhitakerMichael J SmithKenneth E SchmaderGeeta K SwamyGetahun AbatePatricia WinokurWendy BuchananKaitlyn CrossAshley WegelYongxian XuInci YildirimSatoshi KamidaniNadine RouphaelPaul C RobertsMark J MulliganEvan J AndersonPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Administering AS03 adjuvant with the second H7N9 IIV dose and extending the boost interval to 4 months resulted in higher peak antibody responses. These observations can broadly inform strategic approaches for pandemic preparedness. (NCT03589807).